Phase 3 N=20 Comparison of Efficacy, Safety and Tolerability of Two Different 810 nm Diode Lasers for Hair Reduction
Hypertrichosis
Primary: Change in Hair Growth — 57.6; 52.1; 39.3; 29.9 % hair reduction — p=0.2879
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=751 A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
Type 2 Diabetes Mellitus
Primary: Change From Baseline in Hemoglobin A1C at Week 54 — -0.30; -0.48 A1C (%)
N/A N=220 AVAREG Study: An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Breast Cancer
Breast Cancer
Primary: Progression Free Survival — 9.3 months
N/A N=5,521 HALO Patient Registry: Ablation of Barrett's Esophagus
Barrett Esophagus
Primary: Endoscopic Clearance Rate for Barrett's Esophagus-Percentage of Patients With no Endoscopically Visible Barrett's Esophagus at 1 Year Follow-up — 62.1 percentage of…
N/A N=124 An Observational Study of Mircera (Methoxy Polyethylene Glycol-Epoetin Beta) in Chronic Kidney Disease Patients on Dialysis With Renal Anemia
Anemia
Primary: Mean Age of Participants Treated With C.E.R.A — 48.1 Years
N/A N=251 Office Based Intervention to Reduce Bottle Use in Toddlers: TARGet Kids! Pragmatic Randomized Trial
Educational Intervention and Toddler Bottle Use
Primary: Change in Iron Depletion — 88; 83; 12; 17 percentage of participants
Phase 2 N=43 Trial of RAD001 and Erlotinib With Recurrent Head and Neck Squamous Cell Carcinoma
Head And Neck Cancer
Primary: 12-Week Progression-Free Survival (PFS) — 48.57 Percentage of Participants
Phase 3 N=193 Safety and Efficacy of Eslicarbazepine Acetate Monotherapy in Subjects With Partial Epilepsy Not Well Controlled by Current Antiepileptic Drugs
Epilepsy With Simple or Complex Partial Onset Seizures
Primary: Cumulative 112-day Exit Rate as Estimated by Kaplan-Meier Method — 0.444; 0.287 proportion of participants
Phase 1 N=12 PET Trial to Assess the Receptor Occupancy of Brexpiprazole in Adult Subjects With Schizophrenia
Schizophrenia
Primary: Change in Percentage Dopamine D2/D3 Receptor Occupancy — 36; 59; 2; 13 percentage occupancy
Phase 2 N=65 Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia
Chronic Lymphocytic Leukemia
Primary: Tolerability of Rituximab, Cyclophosphamide and Fludarabine in Patients With Previously Untreated CLL/SLL — 42 participants
N/A N=647 HPV Vaccination: An Investigation of Physician Reminders and Recommendation Scripts
Human Papilloma Virus Infection Type 11 · Human Papilloma Virus Infection Type 16 · Human Papilloma Virus Infection Type 18
Primary: First Dose HPV Vaccine Uptake — 118; 63; 117 Participants
N/A N=28 Powered Seating Function Usage Among Veterans - Compliance and Coaching
Use of Power Wheelchairs and Power Seat Functions
Primary: Compliance Rate — 8.9; 39.7 Percentage of participants' compliance — p=0.27
Phase 1 N=43 21 Day Cumulative Skin Irritation of RUT058-60
Irritation/Irritant
Primary: Cumulative Irritation Score of RUT058-60 Hypochlorous Acid Solution (106 mg/L) on Healthy Human Skin — 1.00; 2.46; 1.34; 0.58 units on a scale
Phase 2 N=39 A Trial of Gemcitabine, Infusional 5-Fluorouracil and Cisplatin for Advanced Pancreatic and Biliary Cancers
Pancreatic Cancer · Biliary Cancer
Primary: The Percentage of Untreated and Previously Treated Patients That Had a Partial Response to Treatment — 40; 7.1 percentage of patients
Phase 3 N=136 Smoking Termination Enhancement Project (STEP)
Smoking
Primary: Percentage of Participants Who Abstained From Smoking at 10 and 30 Weeks Post Quit Day — 5; 9; 4; 9 number of participants